|
Match
|
Document |
Document Title |
|
|
7612195 |
Retroviral vectors for delivery of interfering RNA
Provided herein are retroviral vectors for delivering interfering RNA into cells.
|
|
|
7611843 |
Eubacterial tmRNA sequences and uses thereof
The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and...
|
|
|
7612185 |
Nucleic acid biosensors
Sensors comprising aptazymes capable of detecting the presence and concentration of effectors, as well as methods of using such sensors, are disclosed.
|
|
|
7608707 |
siRNA targeting survivin
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene...
|
|
|
7608257 |
Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus...
|
|
|
7608597 |
Methods and compositions for treating hepatitis C virus
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a...
|
|
|
7608705 |
Oligonucleotides, agents containing these oligonucleotides, and the use thereof
The invention relates to particular oligonucleotides, pharmaceutical agents that contain these oligonucleotides, and to the therapeutic use thereof. The oligonucleotides are, in particular, capable...
|
|
|
7608422 |
Simian immunodeficiency virus (SIV) molecular clone encoding mutant gag gene lacking inhibitory/instability regions
Nucleic acid constructs containing HIV-1 gag/pol and SIV gag or SIV env genes which have been mutated to remove or reduce inhibitory/instability sequences are disclosed. Viral particles and host...
|
|
|
7608706 |
siRNA targeting ras-related nuclear protein
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7605141 |
Nucleic acid antioxidant compositions, methods for obtaining such compositions and formulations thereof
Compositions containing purified nucleic acid wherein the nucleic acid acts as an antioxidant. Such compositions also include materials subject to oxidative damage such as antioxidants, vitamins,...
|
|
|
7605251 |
Compositions and methods for inhibiting expression of the PCSK9 gene
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, comprising an antisense strand having...
|
|
|
7605140 |
Regulation of angiogenesis with zinc finger proteins
Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation...
|
|
|
7605252 |
siRNA targeting kinase insert domain receptor (KDR)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7605139 |
DNA cancer vaccines
A plurality of DNA cancer vaccines and their uses in treating cancer are disclosed. Genes encoding Mycobacterium bovis bacillus Calmette-Guérin ( M. bovis BCG) recombinant antigens and genes...
|
|
|
7605142 |
Expression of cyclin G1 in tumors
A method of treating a tumor (in particular osteosarcoma or Ewing's sarcoma) in a host by administering to a host or to the tumor cells an agent which inhibits cyclin G1 protein in an amount...
|
|
|
7605138 |
Nucleic acid compositions for stimulating immune responses
The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.
|
|
|
7601699 |
Production of reprogrammed cells with restored potential
A method for treating cells and/or nuclear transfer units and/or stem cells in culture with such compounds, individually or in combinations, is described. The method results in a globally...
|
|
|
7601698 |
Polypeptide
The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least...
|
|
|
7601700 |
Modulation of eIF4E expression
Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid...
|
|
|
7601697 |
Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The...
|
|
|
7601696 |
Oct-1 as an oncoprotein and use of nucleic acid inhibitors of Oct-1 for cancer treatment
Oct-1 is shown to be an oncoprotein because of its known role as an activator of the histone H2B gene and the importance of this gene during DNA synthesis. To determine the role of Oct-1 as an...
|
|
|
7598225 |
Generation of immune response to prostate-specific antigen (PSA)
We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA),...
|
|
|
7598227 |
Modulation of apolipoprotein C-III expression
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein...
|
|
|
7598228 |
Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1
A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding...
|
|
|
RE40930 |
Porcine adenovirus type 3 genome
The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells...
|
|
|
7598370 |
siRNA targeting polo-like kinase-1 (PLK-1)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7598226 |
Compositions and methods for the therapy and diagnosis of breast cancer
Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic...
|
|
|
7598229 |
Metastatic colorectal cancer vaccine
The invention relates to prophylactic and therapeutic vaccines for protecting individuals against metastatic colorectal cancer and for treating individuals who are suffering from metastatic...
|
|
|
7595301 |
Staple type oligonucleotide and drug comprising the same
Conventional oligonucleotides are opened at both ends and thereby unstable. Their stability against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes...
|
|
|
7595388 |
siRNA targeting EPH receptor A3 (EPHA3)
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene...
|
|
|
7595302 |
Nucleic acids useful for triggering tumor cell lethality
The invention relates to double-stranded nucleic acid fragments comprising a chemically modified backbone and at least 4-1000 bp, preferably 8-500 bp, and most preferably 16-200 bp. The disclosed...
|
|
|
7595306 |
Method of treating neurodegenerative disease
Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA...
|
|
|
7595303 |
Genetic adjuvants for immunotherapy
The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of...
|
|
|
7595305 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an...
|
|
|
7595304 |
Polymeric oligonucleotide prodrugs
Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed.
|
|
|
7595387 |
Modified polynucleotides for reducing off-target effects in RNA interference
Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference...
|
|
|
7592322 |
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such...
|
|
|
7592444 |
siRNA targeting myeloid cell leukemia sequence 1
Efficient sequence specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology. By selecting particular siRNAs directed to myeloid cell leukemia...
|
|
|
7592321 |
Methods of treating lysosomal storage related diseases by gene therapy
Isolated nucleic acid-based vectors and lentivirus vectors, and methods of using those vectors to inhibit or prevent metabolic disorders in a mammal, are provided.
|
|
|
7592323 |
TRPM-2 antisense therapy
It has now been determined that antisense therapy which reduces the expression of TRPM-2 provides therapeutic benefits in the treatment of cancer. In particular, such antisense therapy can be...
|
|
|
7592317 |
Constitutive gene expression in conjuction with ionizing radiation
The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or...
|
|
|
7592319 |
Uses of DNA-PK
This invention provides a method for increasing the susceptibility of a cell to DNA-damaging agents, comprising introducing into the cell an antisense oligonucleotide that specifically hybridizes...
|
|
|
7592441 |
Liver cancer-related nucleic acids
Described herein are novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that...
|
|
|
7592325 |
Methods and compositions for the treatment of eye disorders with increased intraocular pressure
The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules...
|
|
|
7592320 |
Cancer gene therapy based on translational control of a suicide gene
A novel gene therapy for cancer has been discovered, which unlike most prior approaches, does not require specific knowledge of the cancer cells, but instead targets a general characteristic that...
|
|
|
7592324 |
RNAi-mediated inhibition of ocular targets
RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension....
|
|
|
7592318 |
88kDa tumorigenic growth factor and antagonists
This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88...
|
|
|
7589189 |
Inhibition of the expression of huntingtin gene
It is intended to provide methods for suppressing the huntington gene expression by using a double-stranded RNA (dsRNA), huntington gene expression inhibitors to suppress the huntington gene...
|
|
|
7589073 |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic...
|
|
|
7589072 |
Inositol-based molecular transporters and processes for the preparation thereof
Inositol derivatives in accordance with the present invention are effective in significantly enhancing the transportation of various therapeutic molecules across a biological membrane, which may...
|